Published in Lab Law Weekly, September 28th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at ViaCell, Inc.
Report 1: ViaCell, Inc. (Nasdaq: VIAC) announced that it has received FDA approval of its investigational device exemption (IDE) supplement for its ViaCyte(SM) pivotal clinical trial. The pivotal study will evaluate ViaCyte, an investigational product being studied for the cryopreservation and thawing of human oocytes for use during assisted reproductive technology. FDA approval of the IDE supplement allows the Company to enroll women into the study and commence in vitro fertilization...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.